Moderna, Inc. $MRNA Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc reduced its holdings in Moderna, Inc. by 74.7%, now owning 80,017 shares valued at approximately $2.27 million.
• Several institutional investors have increased their stakes in Moderna, with Northern Trust Corp boosting their holdings by 13.6% during the fourth quarter.
• Moderna reported a quarterly revenue of $142 million, which is a 41.1% decline from the previous year, while its earnings per share came in at ($2.13), surpassing estimates.

Aberdeen Group plc lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 74.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,017 shares of the company's stock after selling 235,895 shares during the quarter. Aberdeen Group plc's holdings in Moderna were worth $2,267,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Voloridge Investment Management LLC boosted its position in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after purchasing an additional 1,996,003 shares during the period. Invesco Ltd. boosted its position in shares of Moderna by 17.5% during the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock worth $166,801,000 after purchasing an additional 877,162 shares during the period. Nuveen LLC purchased a new position in shares of Moderna during the 1st quarter worth approximately $19,510,000. Deutsche Bank AG boosted its position in shares of Moderna by 54.7% during the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after purchasing an additional 669,614 shares during the period. Finally, TB Alternative Assets Ltd. purchased a new position in shares of Moderna during the 1st quarter worth approximately $18,495,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Barclays cut their price objective on Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a report on Monday, August 4th. Morgan Stanley reiterated an "equal weight" rating and issued a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. Royal Bank Of Canada cut their price objective on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Bank of America cut their price objective on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a report on Tuesday, July 22nd. Finally, Citigroup assumed coverage on Moderna in a report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $42.88.

Moderna Price Performance

NASDAQ MRNA traded up $0.90 during trading hours on Friday, hitting $27.12. 9,158,832 shares of the company were exchanged, compared to its average volume of 8,387,155. The company has a 50 day moving average of $29.18 and a two-hundred day moving average of $29.05. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $84.28.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The company had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. During the same quarter in the prior year, the business earned ($3.33) EPS. Moderna's revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.